Phase II Study Using the Administration of Autologous T-Cells Genetically Engineered to Express T-Cell Receptors Reactive Against Mutated Neoantigens in People With Metastatic Cancer, including Pancreatic Cancer
The purpose of this phase II study is to see if gene transfer with or without pembrolizumab therapy shrinks tumors.
Study ID: 180049
Trial Phase: Phase II
Trial Sponsor: National Cancer Institute (NCI)
Therapies Used in This Trial: Aldesleukin, Fludarabine, Pembrolizumab, Autologous tumor infiltrating lymphocytes (TIL)